Comparisons

Retatrutide vs CagriSema

Direct Answer

Both retatrutide and CagriSema are investigational obesity drugs. Neither is FDA approved. Retatrutide is a triple GLP-1/GIP/glucagon agonist; CagriSema combines cagrilintide (amylin analogue) with semaglutide (GLP-1 agonist). Retatrutide has Phase 3 topline data; CagriSema has Phase 3 data. No head-to-head trial exists.

What Is CagriSema?

CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), developed by Novo Nordisk. Phase 3 data showed approximately 22.7% weight loss at 68 weeks. It uses a different mechanism from retatrutide — amylin receptor agonism combined with GLP-1, rather than triple GLP-1/GIP/glucagon agonism.

Mechanism Differences

Retatrutide

Triple agonist: GLP-1 + GIP + glucagon receptors. Glucagon receptor activation increases energy expenditure and reduces hepatic fat.

Developer: Eli Lilly

CagriSema

Dual mechanism: GLP-1 receptor agonism (semaglutide) + amylin receptor agonism (cagrilintide). Amylin slows gastric emptying and reduces appetite through central mechanisms.

Developer: Novo Nordisk

Efficacy Evidence

Drug	Trial	Weight Loss	Duration	Status
Retatrutide 12 mg	TRIUMPH-1 (Phase 3)	~28.3% mean	80 weeks	Topline; peer review pending
CagriSema 2.4/2.4 mg	REDEFINE 1 (Phase 3)	~22.7% mean	68 weeks	Published

Cross-trial comparison only — different populations, durations, and protocols. Not a head-to-head result. Neither drug is FDA approved.

Major Unknowns

—No head-to-head trial comparing retatrutide and CagriSema exists

—Long-term cardiovascular outcomes for both drugs are under study

—FDA approval timelines for both drugs are uncertain

—Comparative safety profiles are not established

—Peer-reviewed Phase 3 publications for retatrutide are pending

Questions about retatrutide? A licensed physician can review your case.

Start Physician Review